Diagnostics developer Healthlinx Ltd hopes to have a multi-marker blood test for ovarian cancer on the market in the second quarter of calendar 2008, after successfully completing a Phase II bio-marker trial on its OvPlex test.
Diagnostics developer Healthlinx Ltd hopes to have a multi-marker blood test for ovarian cancer on the market in the second quarter of calendar 2008, after successfully completing a Phase II bio-marker trial on its OvPlex test.
